Skip to main content
SpringerLink
Log in

High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy

  • Correspondence
  • Published:
Bone Marrow Transplantation Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385:46–58.

    Article  CAS  PubMed  Google Scholar 

  2. D’Souza A, Dispenzieri A, Wirk B, Zhang M, Huang J, Gertz MA, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015;33:3741.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Kastritis E, Minnema MC, Dimopoulos M, Merlini G, Theodorakakou F, Fotiou D, et al. Efficacy and safety of daratumumab monotherapy in newly diagnosed patients with stage 3B light chain amyloidosis: a phase 2 study by the European Myeloma Network. Blood. 2021;138:2730.

    Article  Google Scholar 

  4. Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136:71–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Lentzsch S, Lagos GG, Comenzo RL, Zonder JA, Osman K, Pan S, et al. Bendamustine with dexamethasone in relapsed/refractory systemic light-chain amyloidosis: results of a phase II study. J Clin Oncol 2020;38:1455.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130:597–605.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sanchorawala V, Shelton AC, Lo S, Varga C, Sloan JM, Seldin DC. Pomalidomide and dexamethasone Win the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood. 2016;128:1059–62.

    Article  CAS  PubMed  Google Scholar 

  8. Chakraborty R, Bhutani D, Maurer MS, Mohan M, Lentzsch S, D’souza A. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer J. 2023;13:172.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Forgeard N, Elessa D, Carpinteiro A, Belhadj K, Minnema M, Roussel M, et al. Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series. Blood J. 2024;143:734–7.

  10. Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, et al. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2024;109:906–14.

  11. Gustine JN, Staron A, Szalat RE, Mendelson LM, Joshi T, Ruberg FL, et al. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study. Am J Hematol. 2022;97:1189–99.

    Article  PubMed  Google Scholar 

  12. Staron A, Burks EJ, Szalat RE, Sanchorawala V. Prospective Evaluation of Measurable Residual Disease (MRD) and Sustainability of the Response in Patients with Systemic AL Amyloidosis Treated with Daratumumab. Blood. 2023;142:3405.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA

    George S. Mellgard

  2. Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY, USA

    Divaya Bhutani, Markus Y. Mapara, Suzanne Lentzsch & Rajshekhar Chakraborty

  3. Division of Cardiology, Columbia University Irving Medical Center, New York, NY, USA

    Mathew S. Maurer

  4. Division of Nephrology, Columbia University Irving Medical Center, New York, NY, USA

    Jai Radhakrishnan

Authors
  1. George S. Mellgard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Divaya Bhutani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Markus Y. Mapara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mathew S. Maurer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jai Radhakrishnan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Suzanne Lentzsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rajshekhar Chakraborty
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

GSM, MYM, and RC conceived the study design. GSM collected patient data from electronic medical records. DB, MYM, MSM, JR, SL, and RC performed patient care. GSM wrote the first draft of the manuscript. DB, MYM, MSM, JR, SL, and RC critically reviewed the first draft and approved the final draft of the manuscript.

Corresponding author

Correspondence to Rajshekhar Chakraborty.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mellgard, G.S., Bhutani, D., Mapara, M.Y. et al. High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy. Bone Marrow Transplant (2024). https://doi.org/10.1038/s41409-024-02301-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41409-024-02301-7

  • Springer Nature Limited

Search

Navigation